Garde Capital’s Voyager Therapeutics VYGR Stock Holding History

Garde Capital’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20	Closed	-$63	–	800
2025 Q2	$63	Hold	20	–	–	﹤0.01%	823
2025 Q1	$68	Buy	+20	New	+$93	﹤0.01%	812

Other funds holding VYGR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Garde Capital's VYGR Position: Q3 2025 in Review

Garde Capital sold out of Voyager Therapeutics (VYGR) in Q3 2025, closing a stake of 20 shares — an estimated $63 sold.

Garde Capital first reported a position in VYGR in Q1 2025 and held it in 2 quarters. The position peaked at $68 in Q1 2025. 117 funds tracked by Wall St. Rank hold VYGR as of Q3 2025.

Garde Capital reported no remaining Voyager Therapeutics position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 20 Voyager Therapeutics shares in Q3 2025, an estimated $63.
Garde Capital first reported a position in Voyager Therapeutics in Q1 2025 and held it in 2 quarters.
Garde Capital's Voyager Therapeutics position peaked at $68 in Q1 2025.
117 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.